CTX TNA2

Description

CTX TNA2 is a transformed type I astrocyte cell line derived from the frontal cortex tissue of a neonate Sprague-Dawley rat. This transformed cell line exhibits fibroblast-like morphology and adherent growth properties, with a doubling time of approximately 40–50 hours under standard culture conditions. CTX TNA2 was generated by transfecting the SV40 early region oncogene under the control of the human glial fibrillary acidic protein (GFAP) promoter, ensuringastrocyte lineage specificity. This genetic modification leads to stable expression of SV40 T-antigen in over 95% of cells. Despite transformation, approximately 20% of CTX TNA2 cells retain GFAP expression, a hallmark for astrocytic identity. While the cell line lacks type II astrocyte markers (O4/A2B5) and shows reduced transferrin production compared to primary astrocytes. CTX TNA2 is non-tumorigenic in immunocompromised mice. This cell line serves as a valuable model for studying astrocyte functions in neurological research.

Application

• CTX TNA2 serves as a robust and reproducible model for neuroscience and neurobiological research, particularly in studies related to astrocyte biology, central nervous system (CNS) development, and glial cell signaling. It plays a pivotal role in elucidating the biochemical and physiological properties of astrocytes under controlled conditions. When co-cultured with primary porcine brain endothelial cells, CTX TNA2 contributes to the formation of in vitro blood-brain barrier (BBB) models, enabling the study of BBB function, integrity, and permeability. These models are instrumental in drug delivery, neuroinflammation, and neuropharmacology research, making CTX TNA2 a valuable tool for advancing our understanding of brain homeostasis and therapeutic strategies targeting the CNS.